Open AccessThe relationship of serum endocan levels and anti-TNF-alpha therapy in patients with ankylosing spondylitis
Author(s) -
Fatma Zehra Kadayıfçı,
Makbule Gezmen Karadağ
Publication year - 2018
Publication title -
european journal of rheumatology :/european journal of rheumatology
Language(s) - English
Resource type - Journals
eISSN - 2147-9720
pISSN - 2148-4279
DOI - 10.5152/eurjrheum.2017.17287
Subject(s) - ankylosing spondylitis , medicine , tumor necrosis factor alpha , triglyceride , alpha (finance) , pathogenesis , cytokine , gastroenterology , interleukin 6 , immunology , cholesterol , surgery , construct validity , patient satisfaction
Endocan is a marker for vascular pathogenesis and important mediator of angiogenesis that strongly associates with inflammation and vascular diseases. Growing evidence suggest that inflammatory cytokine tumor necrosis factor (TNF-alpha) plays a role in its regulation and secretion, whereas TNF-alpha inhibitors may have the opposite influence. The aim of this research is to investigate the association between serum endocan and anti-TNF-alpha drug treatment in patients with ankylosing spondylitis (AS).